Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ammassari A, Di Filippo A, Trotta MP, et al. Comparison of Demand for Drugs Used for COVID-19 Treatment and Other Drugs During the Early Phase of the COVID-19 Pandemic in Italy. JAMA Netw Open. 2021;4(2):e2037060. doi:10.1001/jamanetworkopen.2020.37060
In February 2020, Italy was the first European country to detect coronavirus disease 2019 (COVID-19) in individuals and rapidly turned into one of the most-affected regions of the world. The National Health Service (NHS), which provides universal coverage to citizens, was challenged as never before in the history of the institution. Because no approved drug was available, patients received potentially effective drugs, participated in clinical trials, accessed compassionate drug use programs, or self-medicated.1 The aim of this study was to evaluate changes in drug demand during the early phase of the COVID-19 outbreak in Italy compared with the period before the outbreak.
Create a personal account or sign in to: